Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Cancer Res. 2012 Feb 13;72(7):1795–1803. doi: 10.1158/0008-5472.CAN-11-3364

Table 2.

Risk of invasive breast cancer associated with rs8170 among white Europeans defined by ER, PR, and HER2 tumor status

N rs8170 Ptrend Case-only
OR (95%CI) Phet
ER Status
 Controls 48,306 1.00 ---
 ER+ 25,649 0.99 (0.96 – 1.02) 0.38 1.61 × 10−5
 ER− 7,641 1.09 (1.05 – 1.14) 6.69 × 10−5
PR Status
 Controls 48,306 1.00 ---
 PR+ 19,996 0.99 (0.96 – 1.03) 0.71 6.52 × 10−3
 PR− 10,444 1.05 (1.01 – 1.10) 7.39 × 10−3
ER/PR Status
 Controls 48,306 1.00 ---
 ER+/PR+ 18,811 0.99 (0.96 – 1.02) 0.60
 ER+/PR− 4,294 0.99 (0.93 – 1.05) 0.66 3.68 × 10−4
 ER−/PR+ 1,102 1.04 (0.93 – 1.16) 0.47
 ER−/PR− 6,092 1.10 (1.05 – 1.16) 4.10 × 10−5
ER, PR and HER2 Status
 Controls 45,684 1.00 ---
 (ER+ or PR+)/HER2− 11,774 1.00 (0.97 – 1.04) 0.80
 (ER+ or PR+)/HER2+ 1,918 1.02 (0.94 – 1.11) 0.62 1.32 × 10−5
 ER−/PR−/HER2− 2,216 1.21 (1.13 – 1.31) 2.97 × 10−7
 ER−/PR−/HER2+ 1,109 0.94 (0.85 – 1.05) 0.31

OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR progesterone receptor; HER2, human epidermal growth factor receptor-2; +, positive; −, negative; Phet, Case-only heterogeneity p-value.